Skip to main content

Table 1 Clinicopathological characteristics and prognostic factors in overall and disease-free survival of patients treated for gastric cancer

From: Adjuvant chemoradiotherapy after d2-lymphadenectomy for gastric cancer: the role of n-ratio in patient selection. results of a single cancer center

Variable No. patients (n=142) Overall survival (5-yr) P Disease-free survival (5-yr) P
Gender
Male 81 58.7% 0.704 54.1% 0.645
Female 61 58.9%   57.7%  
Age
40 years 10 70.0% 0.321 60.0% 0.450
41-69 years 86 62.9%   59.7%  
≥ 70 years 46 49.6%   47.5%  
Gastrectomy
Total 80 49.7% 0.024 43.9% 0.007
Subtotal 62 70.4%   70.4%  
Extended resection
Yes 26 35.5% 0.004 34.6% 0.002
No 116 64.3%   60.6%  
Lymphadenectomy
D1 13 50.5% 0.270 47.8% 0.388
D2 129 59.9%   56.3%  
No. of dissected nodes
Less than 25 39 54.3% 0.339 48.8% 0.269
25 or more 103 60.6%   58.0%  
Location      
Cardia 21 37.0% <0.001 27.7% <0.001
Body 59 60.3%   57.9%  
Antrum 60 66.8%   64.4%  
Linitis 2 0%   0%  
Lauren histology
Intestinal 74 61.4% 0.580 57.1% 0.748
Diffuse 68 55.6%   54.1%  
Lymphatic vessel invasion
Yes 59 48.8% 0.032 44.7% 0.023
No 83 66.7%   63.8%  
Perineural invasion
Yes 67 48.4% 0.015 42.2% 0.003
No 75 68.9%   68.3%  
T-category
T1 11 68.6% 0.005 68.6% <0.001
T2 29 78.4%   71.5%  
T3 11 61.4%   61.4%  
T4a 85 53.8%   51.2%  
T4b 6 33.3%   16.7%  
N-category
N0 40 75.8% 0.002 75.8% 0.005
N1 24 63.8%   57.8%  
N2 42 57.7%   53.6%  
N3a 29 43.4%   39.3%  
N3b 7 14.3%   14.3%  
N-ratio
NR0 40 75.8% 0.005 75.8% 0.001
NR1 39 69.8%   66.3%  
NR2 27 43.7%   39.9%  
NR3 26 36.1%   31.0%  
N-category/N-ratio interaction
N0-NR0 40 75.8% 0.002 75.8% 0.001
N1-NR1a 10 76.2%   76.2%  
N1-NR1b 14 57.1%   45.7%  
N2-NR1 15 79.0%   79.0%  
N2-NR2 and NR3 27 45.1%   39.5%  
N3a-NR2 and NR3 29 43.4%   39.3%  
N3b-NR3 7 14.3%   14.3%